首页> 中文期刊> 《实用心脑肺血管病杂志》 >化疗对小细胞肺癌患者血管内皮生长因子及外周血 T 淋巴细胞亚群的影响

化疗对小细胞肺癌患者血管内皮生长因子及外周血 T 淋巴细胞亚群的影响

摘要

目的:探讨化疗对小细胞肺癌患者血管内皮生长因子(VEGF)及外周血 T 淋巴细胞亚群的影响。方法选取2013年1月—2014年1月在佛山市顺德区第一人民医院就诊并接受化疗的48例小细胞肺癌患者作为观察组,另选取健康献血者和佛山市顺德区第一人民医院健康工作人员共48例作为对照组。观察组患者给予卡铂联合依托泊苷化疗,连续治疗3周为1个疗程。记录对照组及观察组化疗前后血清 VEGF 水平及外周血 T 淋巴细胞亚群,其中外周血 T 淋巴细胞亚群包括 CD +3细胞分数、CD +4细胞分数、CD +8细胞分数及 CD +4/ CD +8细胞比值。结果观察组化疗前血清 VEGF 水平高于对照组(P <0.05);观察组患者化疗后血清 VEGF 水平低于化疗前(P <0.05)。对照组 CD +3细胞分数、CD +4细胞分数、CD +8细胞分数及 CD +4/ CD +8细胞比值高于观察组化疗前,观察组化疗后 CD +3细胞分数、CD +4细胞分数、CD +8细胞分数及 CD +4/ CD +8细胞比值高于化疗前(P <0.05)。结论化疗能有效降低小细胞肺癌患者血清VEGF 水平、改善患者免疫调节能力。%Objective To study the impact of chemotherapy on VEGF and peripheral blood T - lymphocyte subsets of patients with small cell lung cancer. Methods From January 2013 to January 2014 in the First People's Hospital of Shunde District,Foshan,a total of 48 patients with small cell lung cancer were selected as observation group,48 healthy blood donors or hospital worker were selected as control group. Patients of observation group were given carboplatin combined with etoposide, continuously treated for 3 weeks as a course. Serum VEGF level and peripheral blood T - lymphocyte subsets(including CD +3 cell percentage,CD +4 cell percentage,CD +8 cell percentage and CD +4 / CD +8 cell ratio) of the two groups were recorded before and after treatment. Results The serum VEGF level of observation group before treatment was statistically significantly higher than that of control group(P < 0. 05),and serum VEGF level of observation group after treatment was statistically significantly higher than that before treatment(P < 0. 05). CD +3 cell percentage,CD +4 cell percentage,CD +8 cell percentage and CD +4 / CD +8 cell ratio of observation group before treatment were statistically significantly lower than those of control group(P < 0. 05),and above index of observation group after treatment were statistically significantly higher than those before treatment ( P < 0. 05 ). Conclusion Chemotherapy can effectively reduce serum VEGF level and improve the immunoregulation capability of patients with small cell lung cancer.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号